Pluri

Pluri (formerly known as Pluristem Therapeutics Inc.) is a clinical-stage regenerative medicine company founded in Israel in 2003. It focuses on developing cell therapies for a wide range of diseases using placental cells and a 3D cell expansion platform, including various indications for inflammation and ischemia, such as peripheral artery disease, muscle injury, preeclampsia, and graft-versus-host disease.